This is a preview of subscription content, access via your institution.
Literatur
- 1.
Chung HC, Arkenau HT, Lee J, Rha SY, Oh DY, Wyrwicz L, Kang YK, Lee KW, Infante JR, Lee SS, Kemeny M, Keilholz U, Melichar B, Mita A, Plummer R, Smith D, Gelb AB, Xiong H, Hong J, Chand V, Safran H (2019) Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial. J Immunother Cancer 7(1):30. https://doi.org/10.1186/s40425-019-0508-1
- 2.
Wagner AD, Syn NL, Moehler M, Grothe W, Yong WP, Tai BC, Ho J, Unverzagt S (2017) Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD004064.pub4
- 3.
Gulley JL, Rajan A, Spigel DR, Iannotti N, Chandler J, Wong D, Leach J, Edenfield WJ, Wang D, Grote HJ, Heydebreck AV, Chin K, Cuillerot JM, Kelly K (2017) Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. Lancet Oncol 18(5):599–610. https://doi.org/10.1016/S1470-2045(17)30240-1
Author information
Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
M. Hartmann, F. Kütting, H. Alakus und C. Bruns geben an, dass kein Interessenkonflikt besteht.
Rights and permissions
About this article
Cite this article
Hartmann, M., Kütting, F., Alakus, H. et al. Avelumab beim Magenkarzinom: JAVELIN Gastric 100. Onkologe (2021). https://doi.org/10.1007/s00761-021-00918-7
Accepted:
Published: